Qiagen N.V. (QGEN) Earnings Call Transcript & Summary

August 1, 2024

New York Stock Exchange US Health Care Life Sciences Tools and Services earnings

Earnings Call Speaker Segments

Jon Gilardi

executive
#1

Katie, thanks, and hello everyone for being with us on this call. We're glad you're interested in QIAGEN. Joining us today are Thierry Bernard, who serves as our Chief Executive Officer, and Roland Sackers, our Chief Financial Officer. This call is streaming live over the web and will later be available in the investor part of our site, www.qiagen.com. A copy of the quarterly results press release and presentation can also be found on our website; Thierry and Roland will start with their remarks, and a Q&A session will follow. Let's review the Safe Harbor Statement. Everyone should be aware that forward-looking statements will be part of our discussion. Results that actually occur could differ materially from what any such statement projects. The elements that might lead our actual results to differ materially are covered in our latest Form 20-F filed with the SEC, which is also accessible on our website. In addition, some financial measures we'll mention are not prepared under generally accepted accounting principles, or GAAP. Any mention of EPS means diluted EPS. A reconciliation to the most directly comparable GAAP measures appears in our press release and the presentation as well. At this point, I'll turn things over to Thierry.

Thierry Bernard

executive
#2

Thanks, Jon, and hello to all of you — good morning, good afternoon, or good evening depending on where you're joining from — and I appreciate you spending time with us once more. Here at QIAGEN, our teams turned in a powerful performance in quarter two, producing growth against the equivalent stretch of 2023 and also on a sequential basis versus quarter one of 2024; these results, in fact, position QIAGEN among the fastest-expanding businesses in the diversified tools space. They also show how committed we are to accelerating what we do and delivering against the outlook we updated. Reaching our 2024 targets will place us firmly on the road toward the new midterm ambitions we laid out at our capital markets day, all of which hinge on our promise of reliable, profitable growth. Allow me now to walk you through the quarter's highlights. To begin with, QIAGEN once again recorded a period in which we came in above the goals we'd set for both sales and adjusted earnings. Net sales for the quarter reached $496 million, which works out to a 1% rise at CER, meaning constant exchange rates, against the second quarter of 2023. The headline number at CER was $502 million, beating our outlook of at least $495 million by $7 million. If you exclude NeuMoDx, sales climbed 2% CER, and inside our diagnostic solutions product group, they rose 8% CER following our June announcement that the pneumonic system would be discontinued. What powered these results was our business founded on highly recurring revenues, as consumable sales grew 3% CER and accounted for nearly 90% of total sales. One trend affecting the whole industry this quarter was pressure on instrument sales; in quarter two of 2024, our instrument sales as a whole fell 10%, and including NeuMoDx, the drop was 6% CER. Customers are still reluctant to commit capital, and that hesitation carries over to larger instrument purchases as well. Adjusted earnings per share reached $0.55, and $0.55 at CER too. That lands $0.03 above our outlook of at least $0.52. Turning to the second key message: our teams made meaningful product progress throughout the portfolio we bring to customers, covering life science all the way through clinical diagnostics. Let's start with QIAstat, our syndromic testing system. During the second quarter, our teams posted robust growth of 12% at constant exchange rates, and we expect that momentum to strengthen across the back half of the year, fueled by two significant product launches in the U.S. First, after FDA clearance in June, our teams brought the new gastrointestinal panel to market in early July in record time. That was outstanding execution spanning marketing, operations, and the sales force. On top of that, in quarter two we secured FDA clearance for our upgraded respiratory panel, which now covers 21 pathogens, the SARS-CoV-2 virus among them, and it came in at least $1,985,000 at CER, which was $0.3 above our outlook. These milestones act as important catalysts for attracting new customers in the United States, and further new tests are on the way. As for our meningitis and encephalitis panel, U.S. The filings are still tracking to happen this year, and that covers three extra mini panels—one for respiratory targets and two dedicated to gastrointestinal targets. Past that, we're really enthusiastic about QIAstat moving into additional uses alongside our pharma partners in companion diagnostics, which will assist in steering how patients get treated. You may recall that during our capital market day, we mentioned the first pharma partnerships for QIAstat diagnostics are now in place, and they cover panel tests aimed at chronic conditions. Working together with our pharmaceutical partner, the aim is to produce QIAstat assays with results quick enough for use within a clinical visit itself, so a person could walk out holding a prescription when they're eligible for a particular therapy; that's precisely what we're pursuing in clinical molecular diagnostics—making the determination at the pivotal moment. Turning to QuantiFERON, we applaud the revised U.S. American Academy of Pediatrics guidance regarding latent TB testing in children. Children in all age groups may now be tested using QuantiFERON, and that could let more latent TB tests be converted each year; even so, substantial room remains for further QuantiFERON growth, because skin tests still account for well over 50% of the global annual latent TB testing market, the U.S. included. As you know, another key element of our strategy involves reviewing our portfolio against market trends. You saw this once more this year when, in June, we revealed our decision to wind down NeuMoDx. It was genuinely a difficult decision involving what we consider a superb system and a superb platform, but market dynamics changed after the COVID-19 pandemic, and we couldn't find a workable path to move this system forward in a way that generates value. Decisions like this underscore our unwavering commitment to focusing where we can establish profitable leadership positions; and lastly, we've updated our 2024 outlook to reflect the strong core business results in the first half plus the NeuMoDx decision. Our first-half 2024 sales landed roughly $15 million CER above our projection, which was pivotal in our decision to revise the full-year sales outlook to at least $1,985 at CER, while also accounting for our NeuMoDx decision. We've additionally raised the adjusted EPS outlook by $0.02 to $2.16 as we keep our promise of solid profitable growth. That's further underscored by the adjusted operating income margin target of 28.5% of sales and the outstanding free cash flow generation. And now I'd like to hand things over to Roland for a review of the financial results.

Roland Sackers

executive
#3

Thanks, Thierry. Hi everybody. I appreciate your presence on this call too, and it was great to see so many of you at our Capital Market Day. Now I'd like to walk through a few highlights and share some perspective on how we performed. First off, our Q2 results reveal a sequential improvement over Q1 2024, which places us on the path toward hitting the targets we've established for this year. Relative to the first quarter of 2024, non-operational results were essentially unchanged. The adjusted tax rate stood at 19%, while share count came in at 224 million — both matching what we guided. Consequently, adjusted operating income and adjusted net income each climbed 4%, the identical rate. Our strong showing during the first half of 2024, on both the top line and profitability, was instrumental in the upgraded outlook we've issued for this year. Looking at the back half of 2024, we expect to deliver faster year-on-year sales growth, plus better adjusted operating income margin. Let me now explore a few highlights. For Q2, the adjusted operating income margin increased 1 percentage point to 28.4% of sales versus the same period last year; that bolsters our confidence in reaching at least 28.5% for the entire year and moves us toward our 2028 objective of an adjusted margin of no less than 31%; regarding cash flow, free cash flow jumped 56% in Q2 to $129 million compared with a year earlier, and for the first half it climbed an even more striking 86% to $225 million. We're witnessing the effect of efforts aimed at securing a strong rate of cash conversion as adjusted net income keeps rising. Those efforts involve expanding our accounts receivable and accounts payable teams at our WorkLab and Manila hubs. Though we continue monitoring inventory, we're acting to guarantee sufficient supplies so we can prevent disruption, particularly given worries about today's macro conditions and the stability of supply chains. Let me offer a few extra perspectives on our Q2 results. Within the product groups, sales during the second quarter were higher for sample technologies, diagnostic solutions, and PCR nucleic acid amplification versus a year ago. In sample technologies, consumables delivered the 1% CER growth, with especially robust gains in kits utilized on our automation systems. That follows the introduction of upgraded systems, notably QIAcube Connect and EZ2 Connect. Although manual kits showed somewhat softer sales patterns, the rise in automation consumables demonstrates our conversion capability. In diagnostic solutions, we were happy with QuantiFERON's continued strong results, with sales up 11% CER — the fifth quarter in a row exceeding $100 million in revenues. QIAstat-Dx revenue likewise climbed at a strong rate, up 12% CER versus the same period in 2023, driven by meaningful increases in consumables plus a continued healthy level of instrument placements. With the U.S. test menu having recently grown, our confidence is building that we will surpass the 2024 target of at least $100 million in sales; within the PCR product group, QIAcuity posted solid consumable growth. Demand trends for instruments remain favorable too. We are particularly encouraged by interest in the higher throughput QIAcuity 4 and 8 versions, which are favored by biopharma and manufacturing customers along with bigger academic research facilities. Our view is that this will lead to an even larger consumable portfolio. Turning to the genomics and GS product group, QIAGEN Digital Insights sales increased at a high single-digit rate, and we observed positive sales trends across both the research and clinical portfolios. That said, comparisons were difficult against the strong results posted a year earlier. Meanwhile, we expect demand trends for our NGS portfolio to improve during the second half of the year, and we look for this product group to get back to growth, as happened in the first quarter. Let's turn now to regional results. Sales in the Europe, Middle East, and Africa region grew 7% CER, with standout performance in Germany, Italy, and the United Kingdom. QIAstat-Dx sales there were strong, posting double-digit growth in consumables as well as instruments. QuantiFERON also grew above the global average, helped by ongoing conversion away from the tuberculin skin test. In the Americas, sales held steady against the second quarter of 2023, since single-digit consumable growth was canceled out by cautious instrument spending. For Asia-Pacific-Japan, sales fell 3% CER in the second quarter, with higher sales in Japan, Australia, and India leading the way. China's results showed a single-digit CER decline versus the second quarter of 2023, yet grew at a substantial double-digit rate sequentially compared with the first quarter of 2024. At present, we expect difficult macro conditions in China to persist. Let me remind you that China accounts for under 6% of our global sales. Now let's go through the remainder of the income statement. Adjusted gross margin came to 67.2% of sales, roughly 30 basis points higher than the second quarter of 2023, thanks to favorable product mix changes toward more consumable sales. Further margin gains came from reduced operating expenses in R&D, selling and marketing expenses, and administrations during the second quarter relative to the prior-year period. This produced an adjusted operating income margin that expanded by 1 percentage point to 28.4% from the second quarter of 2023, and a notable improvement over the 25.7% margin recorded in the first quarter of 2024. The positive patterns reflect how our programs are affecting cost control effectively, even as we make focused investments to drive growth and back our goal of no less than 28.5% for the entire 2024 year. When it comes to QIAstat-Dx, since that choice was made in June, we saw no meaningful effect on operating costs apart from the restructuring charges recorded during the second quarter, which were left out of adjusted results. That restructuring charge in Q2 amounted to $351 million, and 80% of it was non-cash. Roughly $280 million sat within the cost of goods sold, while around $70 million fell under operating expenses. Our expectation remains that these restructuring charges will reach roughly $400 million by the time the program wraps up in 2025, with approximately 75% tied to non-cash items. Regarding the third quarter of 2024, we presently anticipate that charges tied to this decision will come to somewhere around $30-$40 million. On adjusted EPS, constant exchange rate results landed at $0.55, which is $0.03 above the guidance of at least $0.52. The adjusted tax rate stood at 19%, and the average diluted share count of $224 million matched what we had anticipated. Turning back to cash flow, the second quarter's figures carried forward the strong outcome from the first quarter of 2024. Operating cash flow across the first half climbed 63% to $300 million compared with the equivalent stretch of 2023. On working capital management, accounts receivables dropped by close to $30 million from the close of 2023, and our days of sales outstanding came in at 58 days, staying consistent with this recent pattern. A further factor was inventories coming down by roughly $80 million from the end of 2023. Part of that stemmed from the choice to keep QIAstat-Dx going, but it also reflected gains elsewhere in the portfolio. Free cash flow likewise rose in the first half of 2024, climbing 86% to $225 million versus the first half of 2023. Simultaneously, we recorded higher CapEx levels for software development, among them the upgrade to our SAP system, which is progressing well relative to our plans. Looking at the second half of 2024, we expect a continued robust pace of underlying cash flow generation, mostly matching the levels from the first half of the year, once one-time cash charges tied to restructuring are excluded. That holds true for free cash flow levels too, with CapEx spending similar to what we saw in the first half. On our financing side, we made a payment of roughly $100 million for a German private placement that matured during the second quarter; we also have $500 million in convertible notes maturing in September and expect to need to repay a further $500 million in convertible notes in 2025 as well. I'd now like to hand things back to Thierry.

Thierry Bernard

executive
#4

Appreciate that, Roland. I'd like to walk you through what's happening across our portfolio. Starting with QIAcuity: we're expanding our commercial footprint as we aim to generate strong momentum and capture additional share within digital PCR. As you may recall, our beginning was in academia, followed by biopharma, and at present we're going after additional segments such as forensics and clinical applications. Within forensics, a space where our sample prep offerings have put us in a top three leadership spot, we've entered a new collaboration with the U.S. Federal Bureau of Investigation, the FBI, aimed at creating a digital PCR assay unlike any that has come before. Its purpose is to improve DNA quantification in human samples, strengthening forensic analytics and in the end helping make public safety better. Turning to the clinical segment and digital PCR, the diagnostic version of QIAcuity remains fully on schedule to arrive later this year. The initial assay headed for FDA submission, a BCR-ABL assay intended for hematology patients, likewise remains on track for 2025 approval. There's still plenty of opportunity for expansion in academia and biopharma, and our teams are stepping up campaigns to activate customers. Shifting to QIAGEN Digital Insights, our bioinformatics offering that delivers strong analytics for understanding genomics, we're combining the strength of AI-driven content with curation by humans to deliver the industry's leading bioinformatics portfolio. For results that would have required days or weeks through other choices, customers turn to QDI by QIAGEN and get them in minutes, even seconds. That kind of speed is achievable now. During our capital market days, as you'll recall, we laid out the increased investment flowing into QDI to reinforce this portfolio, which stands apart within our industry thanks to its strong profitability. We're building out our commercial teams by adding sales specialists, and we're putting more into research and development. That supports bringing at least 14 AI-enhanced products to customers by 2028. On sample technologies, let me remind you this forms the basis of what we offer in life science and molecular diagnostics, where QIAGEN opens endless possibilities with DNA and RNA right from the earliest step in numerous lab workflows. We're proceeding with a plan for two significant instrument launches: an upgrade featuring QIAsymphony Connect, scheduled for the second half of 2025, and our move into high-throughput automation, which will be anchored by the QIAsprint Connect launch in early 2026. Bringing this instrument in will raise the capacity to handle close to 200 samples within a few hours. Many new kits are in development and ready to be launched, among them kits for free-circulating DNA and microbiome target isolation. Taken across our portfolio, then, you can see QIAGEN stands stronger than at any point previously. We hold a differentiated portfolio aimed at growth beyond the market we serve, and we'll keep investing to reinforce that differentiation. I'll now hand things back to Roland, who has the details on the outlook.

Roland Sackers

executive
#5

Thanks, Thierry. I'd like to give you some additional perspective now on both our revised 2024 guidance and our outlook for the third quarter. As was noted earlier, we now expect net sales of $1.985 billion CER under the new outlook, versus the prior guidance of at least $2 billion. That figure accounts for a robust first half of 2024, which came in $15 million CER above our outlook, driven in particular by strong results from QIAstat-Dx and QuantiFERON. It also captures a revision tied to the QIAstat-Dx decision, since we now anticipate sales of roughly $25 million CER, down from the earlier target of at least $55 million. Growth should continue to be fueled by consumables and related revenues, whereas larger-scale instrument sales stay difficult. Turning to the third quarter, our guidance calls for net sales of at least $495 million CER, which represents roughly 4% CER growth versus third quarter 2023 sales of $476 million. That figure incorporates an approximate 1 percentage point headwind stemming from the QIAstat-Dx decision. So effectively, that's 5% CER growth on an underlying basis over the third quarter of 2023. This supports the sequential growth we expect for the second half of 2024 relative to the same period in 2023. On adjusted earnings per share, our revised guidance for the year stands at at least $2.16 at CER, an upgrade from the earlier outlook of at least $2.14 CER. I'd also point out that this represents a $0.06 increase over the initial outlook given at the beginning of 2024, reflecting how we are doubling down on our commitment to solid, profitable growth. For the third quarter, adjusted earnings per share should come in at at least $0.55 per share, again at CER, versus $0.50 in the third quarter of 2023 — a solid improvement. Regarding currency effects, given recent movements, we now anticipate an adverse impact of roughly 1 percentage point on full-year net sales and an unfavorable impact of about $0.02 per share on adjusted EPS results. I'll now turn things back over to Thierry.

Thierry Bernard

executive
#6

Thank you very much, Roland, once more — and we're reaching the conclusion of this call. So ahead of opening things up for questions, allow me to briefly recap the main takeaways from today. To begin with, we're extremely happy with how the first six months of 2024 turned out, and with the fact that our company is posting some of the sector's quickest expansion along with gains in profitability. Those strong numbers from the opening half leave us feeling even more assured that we will hit the revised outlook for 2024. Next, the approach we take — one built on balance and focus — keeps showing how valuable it is, as we bring new offerings to market, enhance what we provide to clients spanning life sciences through molecular diagnostics, and take advantage of our extensive worldwide footprint. One crucial piece of this is that close to 90% of what we sell stems from revenues that recur very reliably, which gives our business strength amid a tough macroeconomic backdrop characterized these days by reduced capital spending; as you're aware, we've concentrated on our sharpened growth drivers: QIAcuity, QIAstat, and QIAGEN Digital Insights, the areas where we're stepping up investment to fuel growth. We're also putting money into our well-established leadership in sample technologies, as well as into QuantiFERON. Those primary areas of emphasis don't stop QIAGEN from holding other meaningful avenues for growth, for instance genomics, precision medicine and companion diagnostics, plus HID — human identification and forensics — a space where QIAGEN already ranks among the top players. More than anything, what QIAGEN represents now is the delivery of top-line expansion paired with better profitability, consistent with our pledge of robust, profitable growth over the years ahead. That's precisely what our first-half 2024 results have shown, and we're committed to achieving the same in the back half of the year; having said that, I'd like to turn things back over to John and the operator so we can begin the Q&A. Many thanks for listening.

Catherine Schulte

analyst
#7

Hello, and thank you for taking the question. Perhaps to start, when we look at the guidance for the back half, it seems in the third quarter you're returning to roughly mid-single digits, or growth, and likely finishing the year somewhere in the solid mid-single digit range. How should we view that as a starting point for 2025, and perhaps compare it against the 7% long-term CAGR you presented at your CMD last month? Thanks.

Thierry Bernard

executive
#8

Thank you, Catherine. What I'd say is this demonstrates that we are executing exactly as we told you at the start of the year. As you recall, we made it clear to you and to the market, when we issued our guidance for 2024, that the first half would be slower and then we would gradually pick up speed. Returning to a performance in the second half that would be very similar to how we performed in 2023. That's why our Q3 stands at 4% growth. Strip out NeuMoDx and it's 5% growth, and 5% growth as well in Q4. Q3 will be powered by, first of all, the contribution of new products in our portfolio. During the first half of 2024, you see no effect from the GI approval in the U.S. You see no effect from the QIAcuity diagnostic approval, also in the U.S. That is having an impact in the second half. Second, in the second half, you also have confirmation of the investment we're making, now a bit more than six months in, into our bioinformatics QDI business, and that is going to demonstrate acceleration. Third, you're likely aware that the second half of the year is, by tradition, always stronger and faster in growth for QuantiFERON, since it's affected by high-impact marketing activities, particularly in the U.S., with our back-to-college, back-to-school campaign. So it's essential for us to speed up. We have the pipeline and the portfolio to make that happen, and this would put QIAGEN in position to deliver on the expected three-year plan guidance we provided at our capital market day in New York.

Catherine Schulte

analyst
#9

All right, that's great. Thank you. And it's also good to see consumables getting back to growth. How do you see instruments performing compared with consumables over the second half of the year?

Thierry Bernard

executive
#10

We've consistently told the market that several things are at play here. First, there was a surge in capital sales during the COVID pandemic period. Second, let's keep in mind that this particular year is unusual globally. It's among the rare years when half the world is heading into elections, particularly in important markets like the U.S. Whenever elections happen, people tend to adopt a bit of a wait-and-see stance. So there's definitely some hesitancy around capital spending in many labs, especially within life science. We think this will be temporary; we've always maintained that labs routinely and regularly put money into upgrading their capital sales; so we anticipate this trend will gradually return to normal as we move through 2025.

Michael Ryskin

analyst
#11

Okay, thank you for the question. I'd like to explore a few of the portfolio updates you mentioned, especially on the digital insights side. From what I hear, you're achieving quite a bit there and noticing some momentum in the software business. Could you perhaps discuss how that end market is really doing, the choices customers are making about purchases, and in general what conditions you're observing in genomics? Appreciate it.

Thierry Bernard

executive
#12

Thanks, Michael. As you're aware, we essentially serve two primary categories of customers, something we discussed at our capital market day in June regarding QDI: what we refer to as discovery, encompassing both research and academia clients along with clinical clients. Bioinformatics is in high demand, particularly because of the need for genomics data. Yet the market is also shaped by the reality that with an explosion in accessible genomics data, you still require highly intelligent software so that clinicians and labs can interpret that information—put another way, to convert those trillions of data points into research or clinical insights that can be acted upon. That's what's fueling momentum in this market. What sets QIAGEN apart here is that we've not only put years of investment into artificial intelligence, but we've also established an unmatched knowledge base through many years of manual data curation. It's this blend of automation, AI, and manual curation that distinguishes QIAGEN; furthermore, particularly in contrast to every one of our rivals in this segment, this business is extremely accretive for QIAGEN across the board: gross margin, EBIT margin, EPS, while our competitors are essentially losing money. That's why we see this as a market worth putting resources into for marketing as well as research and development.

Michael Ryskin

analyst
#13

All right, thank you. And if I may fit in one more question about QuantiFERON — a strong quarter, CER growth in the double digits, and it keeps performing well. Of course, plenty has been said regarding possible competition in that space. Another quarter has passed since we heard some updates from would-be competitors further out. I'm just curious whether your discussions with customers have shifted at all, or what you're noticing in the market regarding what people anticipate going forward on that front. Thanks.

Thierry Bernard

executive
#14

Michael, QIAGEN is just like you. We pick up on and pay attention to what competitors say, even when those remarks clash wildly with each other. Still, that isn't where our attention sits. Our top priority is hitting the $450 million guidance for QuantiFERON in 2024. We're tracking well — a fifth straight quarter above $100 million in sales, and once again at a double-digit pace. Next, we need to secure the skin test market, since that's where the primary rivalry lies. Roughly 60 million skin tests are still performed worldwide, and 16.16 million of those happen in the U.S. by itself. So you can see there's plenty of space left for us to expand. Third, we must fulfill the pledge we made at our capital market day in New York: lifting that franchise to $600 million by 2028, which works out to a 7% CAGR. Those are the things we're focused on, and in my view, that's what counts.

Jack Meehan

analyst
#15

Thanks. Morning, everyone. Afternoon, everyone. To kick things off, I'd like to hear your most recent views regarding market trends in life sciences, both for academic and pharma clients. Regarding spending patterns, what's your take on the funding environment and the speed at which things are recovering as we head into the back half?

Thierry Bernard

executive
#16

Jack, I appreciate that question, and my view is that things ought to settle down for one key reason: folks are going to gain steadily greater clarity regarding the funding picture. Keep in mind that during a sizable portion of H1, at least through April, taking the U.S. alone, a lot of labs had no idea what the budget would look like — for NIH 2024, say. Today, they're aware it's unchanged for this year. Will that remain unchanged indefinitely? I doubt it; nothing like that has ever happened in NIH's history, for instance. So we've flagged this restraint when it comes to capital spending, yet I think that considering how powerful innovation is in life science — again, take microbiome. Who even discussed microbiome 6 years back? These days, minimal residual diseases. Annually, there's fresh momentum behind spending or further breakthroughs; that tells us we're quite sure this market will keep expanding. Obviously, capital sales are somewhat weaker this year, though that can't go on indefinitely.

Jack Meehan

analyst
#17

Great. Okay. Then regarding QIAcuity, how are you feeling about how you're doing against that target of over $90 million? It seems to suggest somewhat of an acceleration when it comes to the growth rate during the back half of the year. I'd just really like to hear more regarding your level of confidence there. Thanks.

Thierry Bernard

executive
#18

Thank you, Jack. So to begin with, let's keep in mind that QIAcuity is likely the most rapidly expanding install base that life science has ever seen. From the very first day QIAcuity was launched, we reached an impressive quantity of placements, either converting QPCR customers or winning business away from competitors. Next, it's obvious that since up to now it has primarily been a life science play for QIAGEN, QIAcuity, even though we're seeing solid demand for our instrument, does feel some impact from labs being cautious about CapEx. Yet the positive aspect is that we're broadening QIAcuity's reach along two dimensions. To start, the clinical business — that's the launch plus the approval, the FDA clearance of the platform in the second half — and also pharma. So QIAcuity is now likewise becoming a highly viable solution for companion diagnostic. That's the reason we think the guidance for 2024 of $90 million is within reach.

Dan Arias

analyst
#19

Morning, everyone, and thanks for those questions. Obviously, QuantiFERON is a key product for you all, so I'm curious about it. During the capital markets day, when we talked about keeping your competitive position, a piece of that conversation was simply about workflow. So I'd like to know the timing around a few of those automation enhancements you mentioned. I believe we didn't discuss that—my apologies if we did. Still, automation struck me as one of the essential parts of that offering. So we'd really like to hear when the workflow should shift, and then perhaps how it should get better as time goes on.

Thierry Bernard

executive
#20

I hear you, Dan, and I want to be respectful here. What we kept stressing at the capital market day comes down to a couple of points. The first one is how strong our alliance with DiaSorin is. Keep in mind that theirs is among the biggest installed bases for immunoassays anywhere globally. That means we already have a back-end workflow that is exceptionally competitive. The second point, which the market occasionally overlooks, is that we likewise hold agreements with Tecan and Hamilton, two of the top front-end automation firms. Put those together, and you get an automated workflow that has no equal. Also, what we stated in New York is that our deal with DiaSorin gives us the potential to bring in an automation partner. No formal decision has been made by us. We are looking at the options, and naturally, the market will hear from us at the appropriate time.

Dan Arias

analyst
#21

All right, thank you.

Odysseas Manesiotis

analyst
#22

Hello, and thanks for fielding my questions. The first one concerns Roland and margin; you're sitting at 28.4% for this quarter, which is a solid increase versus Q1. What I'd like to understand is how much of that comes from Nimodecs, and my assumption is that it accounts for two-thirds of the month; and thinking about the later quarters, where you could land and what the exit rate looks like in 2025, it really appears you could push past 29. Does that reasoning hold up? Then I have one quick follow-up.

Roland Sackers

executive
#23

Yeah, thank you, and I appreciate the question. During Q2 of 2024, my view is that Nimodecs had zero material effect on the operational expense line, apart from the structuring charge. That decision was made quite late in the month. Naturally, there are even — I'd probably even make the case that we incurred some additional costs. What matters obviously is that this will shift during the back half of the year and obviously carry forward into the following year as well. I believe we communicated to you and to the market prior to the capital market day that the move away from Nimodecs extends roughly to the middle of 2025. That likewise implies a step-up in the profitability contribution we will encounter as time goes on. And I genuinely believe what you are observing in Q2 is obviously the core business contributing, which — and I want to make this point clearly too — will also keep going. So on both counts we feel at ease that we will obviously be above, or at minimum at, 28.5% across the full year. If you calculate ahead, you obviously notice that we need to move fairly fast to exceed 29% during that year. Still, I believe it provides us obviously with solid reassurance regarding our 2028 target of 31% that we delivered on that. And as we've stated previously, it's starting to be a bigger contribution from the operational expense line. As time passes, there's obviously also a contribution from the gross margin line, even beyond Nimodecs.

Odysseas Manesiotis

analyst
#24

That's all quite clear, thanks. One more question regarding instruments — if I look at instrument sales, they've declined by 10%. There's a remark in there stating this masks what's happening with rental reagents. So I'd like to ask which franchises performed better when it came to instrument placements during H124 versus 2023. Thanks.

Roland Sackers

executive
#25

Apologies, my line was muted. We reported minus 10. For me, the more meaningful figure is closer to minus six, since we halted Nimodecs promotion. Essentially, that base effect needs to be factored in. The key point, Odysseus, is that we're still placing and selling instruments. Thinking we're losing market share would be mistaken. Market penetration keeps growing for QIAcuity, QIAstat, and our sample tech instrument. What we pointed out is that customers, particularly within life science, take somewhat longer to decide, or at times delay, because — as I mentioned earlier — they want greater visibility. So, as we've stated, this is a trend we anticipate and view as fairly short-term. Keep in mind that in life science, it's extremely hard to do placements when instruments can't be sold, yet placements remain possible in clinical; that's precisely why having balance across life science and clinical lets us soften that impact; still, we watch this closely, naturally. But I'll repeat: QIAcuity, QIAstat, and sample tech instruments keep rising in placements each successive quarter.

Doug Schenkel

analyst
#26

Hi there, and good morning — or good afternoon, depending on where you're joining from. Thanks for taking my questions. Thierry, I'd like to kick things off regarding portfolio optimization. First off, a fairly quick one about Nimodecs: might there still be a possibility that a buyer emerges for that asset? I just want to get a baseline on where things stand. Then, second — and this is honestly the bigger point I'm trying to get to — while I recognize that your capital markets day quite reasonably centered on the growth pillars within your portfolio, roughly $600 million in revenue, which I believe represents approximately 30% of total revenue, sits outside those growth drivers. How actively are you looking at alternative paths for pieces of that portion of the business? I'm curious whether additional chances exist to optimize and shift resources around, all while lifting the business's overall growth and margin profile above and beyond what you laid out so impressively in New York about a month ago.

Thierry Bernard

executive
#27

Appreciate that, Doug. To begin with, regarding Nimodecs — a business such as QIAGEN is not, and will never be, dogmatic, yet we must be straightforward: the process has been initiated to discontinue, to wind down that platform. I affirm that this platform is going to be wound down; the thing that matters most right now is moving forward alongside our customers and supporting them so the changeover happens without disruption. Next, from 2020 onward, we have held firmly to that balanced approach and the focus strategy at QIAGEN. Concentrating on growth drivers. That is not to say that beyond those growth drivers there isn't meaningful expansion potential, at times beyond double digits. I shared a few illustrations earlier today. Forensic and HID offers QIAGEN double-digit growth potential. Precision medicine and companion diagnostic represents yet another double-digit growth opportunity for QIAGEN; yet simultaneously, if you recall, particularly Roland's presentation during the capital markets day, we carry that explicit pledge of 250 basis points from where our EBIT margin stands now, taking it past the 31% EBIT margin Roland once more emphasized. And Roland provided certain specifics that it was split among — if you remember the graph — 100 basis points, 50 basis points, and a further 50 basis points spanning various activities, with ongoing portfolio optimization being an essential element. So, as we explained, you notice Nimodecs since it's a major one, but we are vigorously reviewing the remaining portfolio to trim whatever no longer makes sense for QIAGEN or what might perform better within a different company; that is the approach, and it will carry on.

Doug Schenkel

analyst
#28

Thanks for that. And if I could just slip in one quick modeling question for Roland. Roland, in our model, roughly 52% of QuantiFERON sales fall in the second half, with Q3 stronger on a seasonal basis, as has been the case historically. For QIAstat, the back half carries even more, though Q4 has more than Q3. Is that the correct way to think about it directionally?

Roland Sackers

executive
#29

Yes. No, I think it's pretty clear, Hidak, that we hold the view — and I think Thierry made it very plain when he spoke earlier — that we keep believing QIAstat has a solid setup, not just across all the respiratory activity circulating, but obviously at this point, with the GI panel having launched in the U.S., we're able to serve the U.S. market far better, not only through GI, but we clearly can pursue even more tender possibilities; so the effect there will be bigger. QuantiFERON is going to stay and remain strong for the year. I think there's no worry on that front either. I'd still expect QIAstat to also grow sequentially in the third and fourth quarter, simply because of what I just mentioned regarding GI. But don't underestimate either what we ought to see from QIAstat and QIAcuity across the remainder of the year. Thierry was clearly pointing to the investments we made over the course of the year, especially earlier this year into QIA, and QIAcuity has a strong setup, particularly now that we're even selling the larger instruments into that market, which will have an effect on consumable tools as well.

Patrick Donnelly

analyst
#30

Hi, everyone. Appreciate you taking my questions. I've just got one. Regarding China, it seems things improved somewhat on a sequential basis. It doesn't seem like you expect much progress over the remainder of the year. Could you discuss the trends you observed there? Perhaps break things down a bit regarding what's improving, what's deteriorating, and what you anticipate for the rest of the year as we also consider 2025. Thanks, everyone.

Thierry Bernard

executive
#31

Thanks, Patrick. Roland made it clear as well in what he said that, to start, our exposure to that market is fairly limited, slightly under 6% of our sales. The next point is a reaffirmation of what we've been saying repeatedly over the past two years; it's a unique market, yet it's too big a market to overlook. So we're taking every step needed to stay competitive in spite of local challenges. That involves additional localization of our operations in R&D and production for products where it makes sense to go local in China. Next, let me remind you that we're quite differentiated given that we also have a second brand in China; that's a company consolidated with QIAGEN, though it's run differently from QIAGEN locally and sells local products to Chinese companies. And last, we've stated and we reaffirm that we foresee no structural improvement in the market, at minimum until the second half of 2025. Yet again, it represents substantial potential; it's a substantial size; it's the world's second market; it can't be overlooked.

Matt Sykes

analyst
#32

Yeah. I appreciate you answering my questions. Morning to you. You shared a few remarks regarding growing assurance about how the NGS segment is trending upward during the back half. Might you elaborate briefly on what fuels that assurance and on what you're observing within that particular market that points toward gains across the latter six months of this year?

Thierry Bernard

executive
#33

Well, it's a fairly even-handed perspective. It's simply that, as you'll recall, Matt, during 2019, QIAGEN arrived at a highly consequential strategic choice — within genomics along with sequencing, to concentrate on the areas where our strengths and relevance lie. Those areas are chemistry, meaning supplying a platform alongside kits, plus bioinformatics; and across both of those dimensions we turned fully platform agnostic. Moreover, I think the way the market has developed validated that choice, since from 2019 onward, you're witnessing more and more significant competitors emerge in next-generation sequencing past Illumina. Consider PacBio, consider Element, consider Singular, consider MGI, as examples; thus what we provide, in bioinformatics as well as chemistry, matches what those competitors require. That's the reason we stated there's a base effect during Q2 of 2024, yet the market stays quite dynamic, and we deliver value-added solutions. Consequently, the demand exists.

Matt Sykes

analyst
#34

Understood. Then a single brief follow-up, specifically regarding QIAcuity and what you said about share gains. Could you roughly explain the amount you're observing when it comes to pushing out current rivals as opposed to turning those QPCR customers over?

Thierry Bernard

executive
#35

That's a completely fair question, Matt, yet with a platform as highly differentiated as QIAcuity, every opportunity gets pursued by us: a competitive deal, a new deal, meaning conversion of customers toward digital PCR technology. So the wins we get are balanced. What's evident is that because of the system's features, its specific technology, boxes that are fully integrated rather than droplet-based, the capacity to handle various workflows—since, as I remind you, we offer a small workflow, medium throughput, higher throughput, so different needs are addressed by us. Plus, with menu now covered, not just in research academia but biopharma and tomorrow clinical, we possess fundamentally good assets that let us not only prevail against competition but additionally attract newcomers to digital PCR.

Dan Leonard

analyst
#36

Thanks. Just one quick follow-up regarding QIAcuity. Did you provide how fast that platform expanded during the quarter? Then, Thierry, could you assist me in better understanding why the BCR-ABL offering matters? Thank you.

Thierry Bernard

executive
#37

We stated that we experienced substantial, robust, and solid expansion in QIAcuity consumables for Q2. What I can share is that this exceeds double digits. We also mentioned that demand for our platform remains strong, particularly for the higher throughput version.

Dan Leonard

analyst
#38

What about BCR-ABL?

Thierry Bernard

executive
#39

Regarding BCR-ABL, yes, BCR-ABL as well — the approach there, let me start by revisiting the background. Once we chose to take QIAcuity from life science into clinical diagnostics too, a further choice was made: we agreed to concentrate on oncology. Having settled on that oncology focus, a third choice followed. We determined that the area where we'd be highly relevant is what we termed hemato-oncology, and BCR-ABL is its primary marker. So a specific market size isn't something I'll provide. What I will say is that it's the marker that matters most. Next, there's considerable opportunity for demonstrating how a digital PCR method is superior — its capacity to quantify results more precisely compared with other technologies, QPCR in particular. This also makes great sense on our side, since you may recall that we offer a portfolio of hemato-oncology products, known as the Ipsogen product range, which isn't at the close of its life cycle, yet is fairly mature within it. Therefore, shifting it over to digital PCR would prove quite beneficial too.

Falco Fredericks

analyst
#40

Thanks. I'd like to ask about the GI panel launch for the QIAstat. Could you share some perspective on how much of a difference it's already making when you talk with customers? And what's the right way to think about the financial contribution from that panel launch in the second half of this year? Thank you.

Thierry Bernard

executive
#41

Falco, there are two ways you need to look at this. It's precisely what Roland described. First, let's underscore that the very healthy H1 performance on QIAstat, 12% growth, is absolutely not impacted by GI. That demonstrates the strength of the solution. Second, we've always disclosed that part of the QIAstat acceleration for H2 would come from GI. And it's very simple because in the U.S., we had customers already using QIAstat for respiratory, and they were waiting for this new panel to complete their solution to patients. But you also had other customers saying, "I'm very interested, but as long as you don't have at least two panels, I cannot justify the investment." Now they can; so the fact that we have it now, and as I said in my comments, it has been a tremendously quick movement from approval to launch. Explain why QIAstat will be one of our main growth drivers in the second half of the year.

Falco Fredericks

analyst
#42

All right. Thanks very much.

Curtis Wells

analyst
#43

Hello, Curtis Wells here, filling in for Hugo. I appreciate you taking my questions. To start with, I'm looking at the slide on page 8, where you discuss the adjusted EPS outlook for the remainder of the year. From what I can see, you only factored in $0.02 of the $0.03 of outperformance from H1. I'm just wondering, could you provide a bit of color? Did you do this to preserve some flexibility, or perhaps you intend to invest somewhat more than originally planned? Thank you.

Thierry Bernard

executive
#44

Roland, would you like to address the EPS?

Roland Sackers

executive
#45

Absolutely, glad to address that. No, I believe that's a reasonable thing to ask. As you accurately pointed out, we outperformed not just on revenues during Q1 and Q2, but the same was true for EPS. Obviously, we had already raised our guidance considerably when we moved from 10 at the start of the year to 40, and now to 16. At the same time, we reaffirmed that our EBIT margin improvement moves from 28% at present to 28.5%. And as you mentioned, we stated we will clearly see a substantial improvement. And if you run the numbers, you can see that we're actually getting quite near 30% as we exit the year; so I'd say there aren't too many companies around with a profitability profile as strong as ours, and having some space to do even better wouldn't be a bad thing. We'll see.

Curtis Wells

analyst
#46

All right, thank you. If I could get just one more question that returns to QuantiFERON and TB — clearly, results have been fairly solid in H1. Could you perhaps talk about how confident you are that the full year could come in above guidance? And then, maybe tacking this onto the end, we recently gathered, I believe, that Revvity is going to roll out the new workflow in the U.S., with China to follow shortly. Do you think that will affect how intense competition gets, or could it have any effect on your business down the road? Thanks.

Thierry Bernard

executive
#47

Let me take the latter part of what you asked right away, and I'll be direct: every competitor gets our respect. What Revvity has announced is not a new thing. That product is already being sold. Up to now, it hasn't altered the growth paradigm for QuantiFERON, nor has it altered how market shares are divided between the two companies. We simply wish them the best. Still, it's already being sold, so there's nothing new there. Now, will we exceed guidance? Roland, John, myself, and this whole company always aim to be both ambitious and realistic. So let's start with the guidance of $450 million. Trust us — if exceeding it is possible, we won't wait a moment to do it. That said, let's first reach $450 million.

Dan Brennan

analyst
#48

Finally, and certainly not least, everyone, congratulations on the quarter. Perhaps just one question for Roland to kick things off, regarding the latter half of your margin ramp. So my understanding is you have Pneumatics contributing, what, roughly a point of benefit in the back half? So could you unpack a bit how we should think about gross margins across the various OpEx lines in the back half, and how the leverage is flowing through there?

Roland Sackers

executive
#49

Yeah. No, Dan, that's a good question to have in mind. What I have in mind is that, as I mentioned earlier, we'll be phasing down non-MODEX slightly, correct? Which means there's still a clear effect on our profitability from non-MODEX in the second part as well; so gross margin probably didn't shift a great deal this year; more likely that comes next year. But on the operational side, we definitely do anticipate some incremental impact, once again, step by step, since certain sales and marketing activities and R&D get ramped down earlier than operational activities, though it will take some time. So I think what we'll see is a combination of what I'd describe probably as of today, core improvements. That means business outside non-MODEX continues gaining traction and efficiency, and now MODEX is sliding into that as well.

Dan Brennan

analyst
#50

Great. Then maybe just one more on sample prep. That came in better than we'd anticipated—a nice upside—and excluding COVID, the growth looked quite strong. What are you seeing there? What do you think is happening, and what's assumed in the Q3 and Q4 guidance? One could make the case that some kind of slowdown is built in, which might seem cautious. So could you walk us through the drivers and the assumptions? Thanks.

Thierry Bernard

executive
#51

Sure. The first thing I'd mention is that it's encouraging to see sample tech returning to positive movement. That's the main takeaway. Another key point: we noted that our results were largely fueled by how well we did in automated sample technology. To me, this shows our approach of moving to better instruments is paying off. Keep in mind, QIAcube evolved into QIAcube Connect. EZ1 got replaced by EZ2 Connect, and in New York we revealed plans for two additional platforms. That backs up the approach. It confirms the approach. Meanwhile, for QIAGEN, I'd still describe this market as growing at a low single digit rate. That means our focus has to stay on building out higher-value applications and assets—particularly, as we mentioned in New York, around liquid biopsy, microbiome, and minimal residual disease. If we deliver on that, growth will keep coming in at a low single digit, yet this remains recurring business that is highly profitable.

Jon Gilardi

executive
#52

That brings us to the end of today's conference call. We truly appreciate everyone for joining us. Should you have any questions or comments, please feel free to get in touch with us. Thank you so much.

Operator

operator
#53

Everyone, that brings our conference call to a close. We appreciate your participation, and we hope the rest of your day goes well. Farewell.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Qiagen N.V. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Qiagen N.V. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Qiagen N.V. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.